Literature DB >> 9293925

Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.

P B Vermeulen, L Y Dirix, M Martin, J Lemmens, A T Van Oosterom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9293925     DOI： 10.1093/jnci/89.17.1316

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Authors:  Ronald S Go; Sandra J Lee; Donghoon Shin; Steven M Callister; Dean A Jobe; Robert M Conry; Ahmad A Tarhini; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

Review 2.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

3.  Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice.

Authors:  Lu Wang; Wei-Zhong Wu; Hui-Chuan Sun; Xiao-Feng Wu; Lun-Xiu Qin; Yin-Kun Liu; Kang-Da Liu; Zhao-You Tang
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

4.  Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.

Authors:  R Salgado; P B Vermeulen; I Benoy; R Weytjens; P Huget; E Van Marck; L Y Dirix
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.